We thank Xavier Valette and Damien du Cheyron, Nicolas Martin-Silva and colleagues, and Omar Maoujoud and colleagues for their interest in our Article on treatment of patients with COVID-19 and acute respiratory distress syndrome (ARDS) with the IL-1 receptor antagonist anakinra, published in *The Lancet Rheumatology*.[@bib1]

We agree with Valette and du Cheyron that treating patients with non-invasive ventilation outside the intensive care unit (ICU) can be challenging. However, during the COVID-19 outbreak, our high-volume teaching hospital managed more than 800 patients with pneumonia, and the management of many patients with COVID-19 and ARDS with non-invasive ventilation outside the ICU was simply unavoidable. We have extensive experience with non-invasive ventilation outside the ICU setting; training for medical and nurse personnel, as well as systems for patient monitoring, were implemented at our hospital years before the COVID-19 outbreak and were associated with good clinical outcomes.[@bib2] Nonetheless, our study was not aimed at proposing an intensive care approach to patients with COVID-19 and ARDS. Rather, we aimed to evaluate whether high-dose anakinra might reduce hyperinflammation and result in incremental benefits over the best available treatment, which included maximal respiratory support with non-invasive ventilation outside the ICU.[@bib3]

The derived PaO~2~:FiO~2~ ratio we used in our study[@bib1] was adopted to maximise utility and avoid widespread invasive monitoring in a truly high-intensity situation. As noted by Valette and du Cheyron, it is formally correct that invasive ventilation is required to define ARDS other than mild.[@bib1] However, the aim of this definition was to avoid including transient forms of ARDS. Our patients with COVID-19 clearly did not have transient ARDS, with a median PaO~2~:FiO~2~ ratio of 77 (IQR 68--86) and a positive end-expiry pressure of 10 cm H~2~O at baseline, which could have further worsened even after orotracheal intubation.

We agree with Aouba and colleagues that it is possible that during the initial phases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, even a low dose of subcutaneous anakinra might prevent escalation of inflammation. However, high doses and intravenous administration are likely to be needed to control hyperinflammation and improve clinical outcomes in patients with COVID-19-associated ARDS,[@bib3] and dose escalation is made feasible by the robust record of safety of anakinra.[@bib4] Opportunistic infections are very rare, and the rate of bacteraemia for anakinra-treated patients in our study (4 \[14%\] of 29) was similar to that of patients receiving the standard of care (2 \[13%\] of 16), suggesting that these events were not attributable to the drug. In addition, the frequency of serum liver enzyme elevations was lower in anakinra-treated patients (3 \[10%\] of 29) than those receiving standard of care (5 \[31%\] of 16). Considering our findings in hindsight, we agree with Aouba and colleagues that anakinra should not be discontinued in the presence of moderately elevated liver enzymes, and possibly even in the presence of uncomplicated bacteraemia.

The relationship between autophagy and IL-β secretion has long fascinated scientists, as noted by Nicolas Martin-Silva and colleagues. The prevalent view is that autophagy acts as a regulatory mechanism by removing inflammasome components and intracellular triggers.[@bib5] The clinical significance of autophagy in the context of the host response to SARS-CoV-2 is an area of utmost interest, particularly given the extensive and often controversial use of hydroxychloroquine in this patient population.
